{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Maximum grade per participant of any AE.","groups":[{"description":"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nofatumumab: Given IV\n\nbortezomib: Given SC\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Monoclonal Antibody Therapy)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"Every 30 days for 2 months","title":"Frequency and Severity of Toxicity as Graded According to the Cancer Therapeutic Evaluation Program (CTEP) Common Toxicity Criteria (CTC) Version 4.0","type":"SECONDARY","unitOfMeasure":"participants"}